# Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

> **NCT02642042** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- KRAS Gene Mutation
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02642042
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-18
- **Primary completion:** 2019-05-15
- **Final completion:** 2027-03-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642042, "Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02642042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*